Table 2 Comparison of characteristics and outcome for patients discharged with dual antiplatelet therapy vs. oral anticoagulation in addition to single or dual antiplatelet therapy
DAPT, n = 24 | OAC + (D)APT, n = 29 | p | |
|---|---|---|---|
Age, y (SD) | 76.0 ± 8.2 | 80.2 ± 7.2 | 0.053 |
Female sex, % (n) | 33 (8) | 24 (7) | 0.55 |
Median prestroke mRS (IQR) | 0 (0–1.25) | 0 (0–1) | 0.87 |
Median NIHSS (IQR) | 14 (9–17) | 14 (9–18) | 0.96 |
Median ASPECTS (IQR) | 9 (7–10) | 10 (8–10) | 0.30 |
Cardiovascular risk factors, % (n) | |||
Hypertension | 92 (22) | 90 (26) | 1.0 |
Diabetes | 38 (9) | 14 (4) | 0.06 |
Dyslipidemia | 54 (13) | 55 (16) | 1.0 |
Baseline medication, % (n) | |||
Antiplatelet therapy | 38 (9) | 21 (6) | 0.23 |
Oral anticoagulation | 13 (3) | 48 (14) | 0.008 |
Procedural results | |||
IVT, % (n) | 57 (13) | 28 (8) | 0.048 |
mTICI ≥ 2b, % (n) | 92 (22) | 100 (28) | 0.21 |
Passages, n (IQR) | 1 (1–2) | 1 (1–2) | 0.75 |
Median time SO to ADM (IQR) | 166 (111–200.25)# | 147 (67.5–197.5)+ | 0.70 |
Median time LSW to ADM (IQR) | 300 (241–401.5)# | 633 (426–888)+ | 0.09 |
Median time ADM to GRO (IQR) | 53.5 (33.25–70.75) | 53 (36–107) | 0.50 |
Median time GRO to FLR (IQR) | 61.5 (34.5–75.75) | 54 (36–91) | 0.82 |
Hospital stay | |||
Malignant MCA infarction, % (n) | 0 | 3 (1) | 1.0 |
Recurrent stroke, % (n) | 13 (3) | 17 (5) | 0.72 |
In-stent thrombosis, % (n) | 8 (2) | 0 | 0.20 |
ICH, % (n) | 4 (1) | 17 (5) | 0.20 |
Median NIHSS at 24 h (IQR) | 11 (6–15) | 10 (8–17.50) | 0.82 |
Median mRS at 24 h (IQR | 4 (4–5) | 4 (4–5) | 0.91 |
Median discharge NIHSS (IQR) | 7.5 (3–10.5) | 7 (4–11) | 0.73 |
Median discharge mRS (IQR) | 4 (3–4) | 4 (3–5) | 0.79 |
Median duration of stay, d (IQR) | 9 (7–12.5) | 7.5 (6–17.25) | 0.75 |
Outcome | |||
Median mRS at 90 days (IQR) | 3.5 (2–6) | 3 (2–4) | 0.38 |
mRS 0–2 at 90 days, % (n) | 36 (8) | 42 (10) | 0.77 |
Mortality at 90 days, % (n) | 32 (7) | 4 (1) | 0.020 |